Articles From: UPDATE: Gilead, AbbVie, Denbury in focus to VBL Therapeutics Announces Positive Phase 2a Data for VB-111 in Recurrent Thyroid Cancer


2014/12/22
By MarketWatch, MarketWatch Steelcase to post earnings after Monday's close NEW YORK (MarketWatch) -- These are the stocks that could grab the spotlight Monday, as a holiday-shortened trading week begins: Gilead Sciences Inc.(GILD) is slumping and AbbVie Inc.(ABBV) is gaining after Express Scripts Holding Co.(ESRX) , the largest manager of U.S. prescription-drug benefits, decided an AbbVie drug will be its exclusive option for treating the most common form of hepatitis C.
Sign-up for UPDATE: Gilead, AbbVie, Denbury in focus investment picks
2014/12/22
By Victor Reklaitis, MarketWatch 'Simply no reason to buy Russia,' one strategist says NEW YORK (MarketWatch) -- Russia's stocks performed badly, or uzhasno as Vladimir Putin might put it, while India's stocks registered a terrific 2014 thanks to "Modi mania" -- and each country's equity market easily could stay on its current track in 2015.
Sign-up for UPDATE: Here are the worst countries for investors in 2014 -- and maybe 2015, too investment picks
2014/12/22
Of the 84 components of the S&P 500 Financials sector, 10 are down this year.
Sign-up for UPDATE: How to find 'winners' among the worst -2- investment picks
2014/12/22
By Philip van Doorn, MarketWatch Your research may tell you that some companies have been unfairly punished As we start the holiday week, one way to identify possible stock market presents for 2015 is to look at this year's worst performers.
Sign-up for UPDATE: How to find 'winners' among the worst S&P 500 stocks investment picks
2014/12/22
By Brett Arends, MarketWatch Is a gift to a foreign official really the same as a bribe?
Sign-up for UPDATE: Is your company being 'corrupt'? investment picks
2014/12/22
Then you have the Knicks.
Sign-up for UPDATE: Major league sports' biggest Santas -2- investment picks
2014/12/22
By Jason Notte, MarketWatch Would you pay $676 for your family to see the Knicks?
Sign-up for UPDATE: Major league sports' biggest Santas and Scrooges investment picks
2014/12/22
By Anora Mahmudova and Sara Sjolin, MarketWatch Dow industrials leads Wall Street gains NEW YORK (MarketWatch) -- U.S. stocks continued to build on last week's big Fed-inspired rally, putting the benchmark S&P 500 on track for a record close.
Sign-up for UPDATE: Modest gains for U.S. stock push S&P toward fresh record investment picks
2014/12/22
By MarketWatch, MarketWatch Steelcase to post earnings after Monday's close NEW YORK (MarketWatch) -- These are the stocks that could grab the spotlight Monday, as a holiday-shortened trading week begins: Nabors Industries Ltd.(NBR), Denbury Resources Inc.(DNR) and other energy names will see if they can recover further from their slide in the last few months that's been sparked by crude oil's crash.
Sign-up for UPDATE: Nabors, Denbury, other energy stocks in focus investment picks
2014/12/22
By Anora Mahmudova and Sara Sjolin, MarketWatch Technology, telecoms stocks lead rally NEW YORK (MarketWatch) -- The S&P 500 and Dow Jones Industrial Average ended Monday at new records, fueled by continued hopes that the Federal Reserve won't be in a rush to raise interest rates.
Sign-up for UPDATE: S&P 500, Dow industrials close at records investment picks
2014/12/22
By Liz Moyer Some ultra-rich hire consultants to secure homes, vet staff, protect information It's a dangerous world, no matter how much money you have.
Sign-up for UPDATE: Security risks get wealthy families' attention investment picks
2014/12/22
By Catey Hill, MarketWatch As the holidays near, stores are trying to squeeze every penny from our wallets -- but many shoppers aren't having it.
Sign-up for UPDATE: Shopping today? It pays to compare prices on these things investment picks
2014/12/22
By Wallace Witkowski, MarketWatch Chesapeake narrows regular session loss on buyback plan SAN FRANCISCO (MarketWatch) -- Steelcase Inc. shares declined in the extended session Monday after the office-furnishings company's revenue for the third quarter fell short of Wall Street estimates.
Sign-up for UPDATE: Steelcase shares slide as revenue comes in light investment picks
2014/12/22
By Shawn Langlois, MarketWatch Critical intelligence before the U.S. market opens "Yeah, there's definitely a lot of stingrays out there today," my 11-year-old daughter, ever the alarmist, randomly warned me on Sunday afternoon as we dipped our toes into the water.
Sign-up for UPDATE: Stock market may wish investors a wary Christmas investment picks
2014/12/22
Tesco Corp.
Sign-up for UPDATE: Tesco Corp. warns of profit, sales miss investment picks
2014/12/22
By Carla Mozee, MarketWatch LONDON (MarketWatch) -- U.K. stocks popped higher Monday, with energy shares among the advancers pushing up the benchmark FTSE 100 at the start of the holiday-shortened week.
Sign-up for UPDATE: U.K. stocks bounce up at start of holiday-shortened week investment picks
2014/12/22
By Carla Mozee, MarketWatch LONDON (MarketWatch) -- U.K. stocks rose Monday, though energy shares on the resource-heavy FTSE 100 benchmark pared gains as oil prices began losing ground.
Sign-up for UPDATE: U.K. stocks rise at start of holiday-shortened week investment picks
2014/12/22
By Anora Mahmudova and Sara Sjolin, MarketWatch AbbVie jumps on FDA's hepatitis C drug approval NEW YORK (MarketWatch) -- After a robust snap-back rally last week, U.S. stocks struggled to keep momentum on Monday in a holiday-shortened week.
Sign-up for UPDATE: U.S. stocks edge higher in thin trade investment picks
2014/12/22
By Anora Mahmudova and Sara Sjolin, MarketWatch AbbVie jumps on FDA's hepatitis C drug approval NEW YORK (MarketWatch) -- After a robust snap-back rally last week, U.S. stocks struggled to keep momentum on Monday in a shortened Christmas week.
Sign-up for UPDATE: U.S. stocks struggle to move higher investment picks
2014/12/22
By Anora Mahmudova and Sara Sjolin, MarketWatch AbbVie jumps on FDA's hepatitis C drug approval NEW YORK (MarketWatch) -- U.S. stock futures were slightly higher on Monday amid some year-end deal making in a shortened Christmas week.
Sign-up for UPDATE: U.S. stocks: Futures point to higher open; existing-home sales next investment picks
2014/12/22
By Sara Sjolin, MarketWatch LONDON (MarketWatch) -- U.S. stock futures pointed to a higher open on Monday, as a rally in oil prices lifted global markets and signaled a return to calm for the shortened Christmas week, after the turmoil of earlier in December.
Sign-up for UPDATE: U.S. stocks: Futures point to upbeat open but low-volume day as Christmas nears investment picks
2014/12/22
By Jennifer Booton, MarketWatch Apple's shares of the mobile payments market has hit 1.7% NEW YORK (MarketWatch)-- Apple Inc. users have a love affair with organic food, but they don't mind stretching for a Big Mac sometimes, either.
Sign-up for UPDATE: What are people buying with their iPhones? Big Macs and organic food investment picks
2014/12/22
By Jennifer Booton, MarketWatch Apple's shares of the mobile payments market has hit 1.7% NEW YORK (MarketWatch)-- Apple Inc. users have a love affair with organic food, but they don't mind stretching for a Big Mac sometimes, either.
Sign-up for UPDATE: What do people buy with their iPhones? Big Macs and drugs investment picks
2014/12/22
Levi & Korsinsky is investigating the Board of Directors of Uroplasty, Inc. (“Uroplasty” or “the Company”) (NasdaqCM: UPI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Vision-Sciences, Inc. (NasdaqCM: VSCI). Click here to learn more about the investigation: http://zlk.9nl.com/uroplasty .
Sign-up for UPI SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Uroplasty, Inc. Regarding the Fairness of the Sale of the Company to Vision-Sciences, Inc. investment picks
2014/12/22
All-Stock Combination Creates New Company with Expanded Product Offerings in Urology Conference Call Today at 11:00 AM EST MINNEAPOLIS and ORANGEBURG, N.Y. , Dec.
Sign-up for Uroplasty and Vision-Sciences to Merge, Creating Medical Device Company Positioned for Growth investment picks
2014/12/22
WILMINGTON, Del.
Sign-up for UROPLASTY, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout investment picks
2014/12/22
CHARLOTTE, N.C. , Dec.
Sign-up for UTC Aerospace Systems Recognized as Gold Supplier by the Defense Logistics Agency investment picks
2014/12/22
HOUSTON , Dec.
Sign-up for VAALCO Energy Announces Resumed Production From Ebouri 2-H Well investment picks
2014/12/22
- Vanda and Novartis Agree to Settle Arbitration - Novartis to purchase $25 million of Vanda common stock - Vanda to acquire rights to a Phase II clinical compound from Novartis WASHINGTON , Dec.
Sign-up for Vanda to regain US and Canadian rights to Fanapt® investment picks
2014/12/22
TEL AVIV, Israel, Dec.
Sign-up for VBL Therapeutics Announces Positive Phase 2a Data for VB-111 in Recurrent Thyroid Cancer investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: UPDATE: Gilead, AbbVie, Denbury in focus to VBL Therapeutics Announces Positive Phase 2a Data for VB-111 in Recurrent Thyroid Cancer
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent